A preliminary study of the effect of fluoxetine treatment on the 2:16-α-hydroxyestrone ratio in young women

Therapeutic Drug Monitoring

Volumn 25, Issue 1, 2003, Pages 125-128

  Thompson, Diane S ^a   Kirshner, Margaret A ^b   Klug, Thomas L ^c   Kastango, Kari B ^b   Pollock, Bruce G ^b  

^a QUEEN S MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Immuna Care Corporation   (United States)

Author keywords

16 hydroxyestrone; 2 hydroxyestrone; CYP1A2 and CYP3A4 isoenzymes; Estrogen metabolism

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; ANTIDEPRESSANT AGENT; CAFFEINE; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ESTRONE DERIVATIVE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FLUOXETINE; MESTRANOL PLUS NORETHISTERONE; MONOCLONAL ANTIBODY; MULTIVITAMIN; NICOTINE; ORAL CONTRACEPTIVE AGENT; SERAFEM;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL ARTICLE; DRUG INDICATION; DRUG METABOLISM; ENZYME IMMUNOASSAY; ESTROGEN METABOLISM; FEMALE; HUMAN; MENSTRUAL CYCLE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; SMOKING HABIT; TIME SERIES ANALYSIS; URINALYSIS;

ADULT; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FLUOXETINE; HUMANS; HYDROXYESTRONES; ISOENZYMES; PILOT PROJECTS;

EID: 0037304747     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200302000-00021     Document Type: Article

References (19)

1. Martucci CP, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther 1993;57:237-57.
2. Shou M, Korzekwa KR, Brooks EN, et al. Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 1997;18:207-14.
3. Bradlow HL, Telang NT, Sepkovic DW, et al. 2-Hydroxyestrone: the "good" estrogen. J Endocrinol 1996;150:5259-63.
4. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16-hydroxyestrone to estradiol receptors in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci 1988;85:7831-5.
5. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16αhydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000;11:635-40.
6. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85.
7. Ho GH, Luo XW, Ji CY, et al. Urinary 2/16α-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer. Ann Acad Med 1998;28:294-9.
8. Kelly JP, Rosenberg L, Palmer JR, et al. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol 1999;150:861-8.
9. Cotterchio M, Kreiger N, Darlington G, et al. Antidepressant medication use and breast cancer risk. Am J Epidemiol 2000;151:951-7.
10. Dimmock PW, Wyatt KM, Jones PW, et al. Efficacy of selective serotonin inhibitors in premenstrual syndrome: a systemic review. Lancet 2000;356:1131-6.
11. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002;3:13-37.
12. Parsons WD, Neims AH. Effect of smoking on caffeine clearance. Clin Pharmacol Ther 1978;24:40-5.
13. Zaigler M, Rietbrock S, Szymanski J, et al. Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. Int J Clin Pharmacol Ther 2000;38:235-44.
14. Catteau A, Bechtel YC, Poisson N, et al. A population and family study of CYP1A2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995;47:423-30.
15. Pasagian-Macaulay A, Meilahn EN, Bradlow HL, et al. Urinary markers of estrogen metabolism 2- and 16α-hydroxylation in premenopausal women. Steroids 1996;61:461-7.
16. Westerlind KC, Gibson KJ, Wolfe P. The effects of diurnal and menstrual cyclicity and menopausal status on estrogen metabolites: implications for disease risk assessment. Steroids 1999;64:233-43.
17. Bradlow HL, Sepkovic DW, Klug T, et al. Application of an improved ELISA assay to the analysis of urinary estrogen metabolites. Steroids 1998;63:406-13.
18. Kashuba AD, Bertino JS Jr, Kearns GL, et al. Quantitation of three-month intra-individual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther 1998;63:540-51.
19. Klug TL, Bradlow HL, Sepkovic DW. Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16α-hydroxyestrone in urine. Steroids 1994:59:648-54.